Premium
Immunohistochemical ferritin in hepatocellular carcinoma
Author(s) -
Cohen Cynthia,
Berson Solomon D.,
Shulman Gerald,
Budgeon Lynn R.
Publication year - 1984
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19840501)53:9<1931::aid-cncr2820530921>3.0.co;2-d
Subject(s) - hepatocellular carcinoma , medicine , cirrhosis , hemosiderin , ferritin , immunoperoxidase , gastroenterology , pathology , carcinoma , immunohistochemistry , antibody , immunology , monoclonal antibody
Serum ferritin concentrations are elevated in 35% to 100% of patients with hepatocellular carcinoma (HCC). With an immunoperoxidase technique, ferritin was demonstrated in tumor tissue from 32 of 74 (43%) black southern African patients, and from 12 of 19 (63%) American patients with HCC ( P > 0.1). Ferritin was present in nonneoplastic liver in 82% of African and 100% of American patients ( P > 0.1). Moderate to large amounts of stainable hepatic storage iron (hemosiderin) were present in 76% of African and 67% of American patients ( P > 0.1). Fifty‐two (70%) African patients had macronodular cirrhosis. In the literature, 80% to 90% of American patients with HCC have cirrhosis. High serum ferritin levels in patients with HCC may be due to ferritin production by the tumor, or related to the associated iron overload and/or cirrhosis.